[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"urinary-tract-infection\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:urinary-tract-infection":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,10,0,[8,47,81,112,139,167,196,217,244,273],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":30,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100579319","phase-3-fosfomycin-for-male-urinary-tract-infection-100579319",false,"NCT06822751","FOsfomycin for Male Urinary Tract Infection","Exploratory Pragmatic Trial of Fosfomycin-trometamol Treatment of Male Urinary Tract Infections in Primary Care","FOMUTI","Inclusion Criteria:\n\n* Men aged 18 years or older.\n* Consulting in a primary care setting.\n* Suspected of having a male urinary tract infection (MUTI) by the investigating physician and presenting at least one recent acute symptom (\\\u003C 3 months) from the following:\n\n  * Lower urinary tract symptoms: dysuria, urgency, frequency, hematuria.\n  * Pelvic pain unrelated to urination: suprapubic, perineal, or urethral pain.\n* Patient has read and understood the information letter and signed the informed consent form.\n* Affiliation with a social security system or beneficiary of such a system.\n* No history of illness or psychological or sensory abnormality likely to prevent the subject from fully understanding the conditions required for participation in the protocol or to prevent him\u002Fher from giving informed consent\n\nExclusion Criteria:\n\n* Presence of one or more criteria for severity of infection\n\n  * Severe sepsis or septic shock defined by a qSOFA score ≥ 2\n  * or\u002Fand systolic BP less than 100 mmHg: non-inclusion criterion\n  * or\u002Fand temperature \\\u003C 36°C or \\> 38°C\n  * or\u002Fand diagnosis of pyelonephritis (pain on lumbar percussion)\n  * or\u002Fand presence of abdominal guarding\u002Fcontraction\n  * or\u002Fand presence of a bladder globe above the pubic bone: (suspected acute retention of urine)\n  * or\u002Fand known immunosuppression: any immunosuppressive treatment (including corticosteroid therapy \\> 10 mg\u002Fd for more than 5 days), neutropenia (PNN \\\u003C 500\u002FmL) severe malnutrition (albumin \\\u003C 30 and\u002For BMI \\\u003C 16),\n* No diagnosis of male urinary tract infection in the last 3 months,\n* No ongoing chronic prostatitis,\n* Known urinary tract abnormality: urinary tract lithiasis, vesico-ureteral reflux, prostate or urinary tract cancer, prostate adenoma treated medically or surgically, urinary tract malformation (including single kidney and urethral stricture).\n* Acute retention of urine and indication for surgical or interventional drainage\n* Hyperalgesic form\n* Urinary tract infection associated with care, on urinary catheter or suprapubic catheter\n* Urinary tract surgery, cystoscopy, prostate biopsy or urinary catheterisation less than 3 months old\n* Urinary tract surgery, cystoscopy, prostate biopsy or urinary catheterisation less than 3 months old\n* Severe disease or high probability of death within 3 months,\n* Hypersensitivity to fosfomycin trometamol or to any of the excipients (notable excipients: sucrose, dextrose (source of glucose), maltodextrin (source of glucose), orange yellow colouring S (E110)),\n* End-stage renal disease (creatinine clearance \\\u003C10 mL\u002Fmin),\n* Patients with glucose and galactose malabsorption syndrome or sucrase\u002Fisomaltase deficiency (rare hereditary disease)\n* Antibiotic taken within 72 hours of diagnosis of male urinary tract infection,\n* Major cognitive impairment,\n* Person deprived of liberty by an administrative or judicial decision or person placed under court protection \u002F sub- guardianship or curatorship\n* Any history of illness or psychological or sensory abnormality likely to prevent the subject from fully understanding the conditions required for participation in the protocol or to prevent the subject from giving informed consent.\n* Known non-adherence to treatment,\n* Simultaneous participation in another interventional clinical study,\n* Cannot be taken orally (vomiting)","MALE","18 Years",{"count":20,"type":21},138,"ESTIMATED","INTERVENTIONAL",[24],"PHASE3","Male urinary tract infections (MUTI) are often less recognised compared to those in women. French clinical guidelines practices recommend the use of antibiotics called fluoroquinolones, which are highly effective in treating MUTIs. However, these antibiotics can lead to rare but serious side effects, such as tendonitis or heart rhythm disturbances. Additionally, fluoroquinolones can contribute to the development of bacterial resistance, making their use inadvisable within six months of treatment.\n\nIn response to these concerns, we aim to explore a well-established alternative, fosfomycin trometamol (known by the brand name MONURIL®). This antibiotic has a strong track record in treating UTIs in women, with well-documented benefits and minimal associated risks.\n\nThe primary goal of this study is to assess the effectiveness of fosfomycin trometamol in treating urinary tract infections in men, as well as to evaluate any potential treatment failures.",[27,28,29],"Urinary Tract Infection","Prostatitis","Cystitis",[31,29,27,32,33],"Men","Anti-infective agents, urinary","Fosfomycin","NOT_YET_RECRUITING","2026-06-11",{"date":37,"type":38},"2026-06-12","ACTUAL",{"date":40,"type":21},"2026-07",{"date":42,"type":21},"2029-10",{"name":44,"class":45},"University Hospital, Rouen","OTHER",1,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":53,"eligibilityCriteria":54,"healthyVolunteers":11,"sex":55,"minAge":56,"maxAge":57,"enrollmentInfo":58,"targetDuration":4,"studyType":22,"phases":60,"briefSummary":62,"conditions":63,"keywords":67,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":72,"lastUpdatePostDateStruct":73,"startDateStruct":75,"completionDateStruct":77,"leadSponsor":79,"locationsCount":46},"100633919","phase-4-clinical-efficacy-of-stopping-oral-antibiotics-when-symptoms-stop-compared-to-finishing-the-course-100633919","NCT07532941","Clinical Efficacy of Stopping Oral Antibiotics When Symptoms Stop, Compared to 'Finishing the Course'","StopStop@HITH - Clinical Efficacy of Stopping Oral Antibiotics When Symptoms Stop, Compared to 'Finishing the Course', for Children With Bacterial Infections Through Hospital-in-the-Home (HITH): a Basket Randomised Controlled Trial (RCT)","StopStop@HITH","Inclusion Criteria:\n\n1. Between the ages of ≥ 1 years and ≤ 17 years at enrolment\n2. Diagnosis of cellulitis, urinary tract infection (UTI), lower respiratory tract infection (LRTI) or lymphadenitis\n3. Prescription of oral antibiotics as a switch from IV antibiotics\n\nExclusion Criteria:\n\n1. Clinician determined need for \\>10-day oral antibiotic course\n2. Child with immunosuppression (e.g. as a result of cancer treatment)\n3. Second episode of same bacterial infection within the last 28 days\n4. Child is unable to take oral antibiotics\n5. Previous enrolment in StopStop@HITH\n6. Parent\u002Fguardian does not speak English\n7. Clinician determined need for 10-day course of oral antibiotics for treatment\u002Fclearance of streptococcal infection\n8. UTI only: known impaired renal function (e.g. renal transplant patients or known chronic renal failure)\n9. LRTI only: known chronic respiratory condition (e.g. cystic fibrosis or bronchiectasis) or need for long term respiratory support (e.g. home oxygen, Continuous Positive Airway Pressure \\[CPAP\\] or tracheostomy); empyema or lung abscess","ALL","1 Year","17 Years",{"count":59,"type":21},200,[61],"PHASE4","The aim of the StopStop@HITH study is to see if stopping antibiotics when symptoms stop is as good as finishing the course of antibiotics. The study will enrol children at the Royal Children's Hospital who are prescribed oral antibiotics after completing a course of intravenous (IV) antibiotics for the treatment of cellulitis, urinary tract infection (UTI), lower respiratory tract infection (LRTI) and lymphadenitis.\n\nThe aims of the study are:\n\n* To determine if oral antibiotics can be safely stopped once symptoms stop in children with cellulitis (who have completed a course of IV antibiotics).\n* To assess feasibility of a larger study of other common infections across multiple hospitals.\n\nThe participants parent\u002Fguardian will complete a daily symptom tracker for the duration of the prescribed oral antibiotic course and attend a telehealth appointment with the study team once the participants symptoms have resolved. There are additional follow up surveys at day 14, day 28 and day 180.",[27,64,65,66],"Cellulitis","Respiratory Tract Infections","Lymphadenitis",[68,69,70,71],"Infection","Antibiotics","Paediatrics","Symptom Guided","2026-04-08",{"date":74,"type":38},"2026-04-16",{"date":76,"type":21},"2026-06",{"date":78,"type":21},"2028-06",{"name":80,"class":45},"Murdoch Childrens Research Institute",{"id":82,"slug":83,"hasResults":11,"nctId":84,"briefTitle":85,"officialTitle":86,"acronym":87,"eligibilityCriteria":88,"healthyVolunteers":11,"sex":17,"minAge":89,"maxAge":90,"enrollmentInfo":91,"targetDuration":4,"studyType":22,"phases":93,"briefSummary":94,"conditions":95,"keywords":96,"overallStatus":101,"whyStopped":4,"lastUpdateSubmitDate":102,"lastUpdatePostDateStruct":103,"startDateStruct":105,"completionDateStruct":107,"leadSponsor":109,"locationsCount":111},"100632010","phase-4-topical-steroids-to-prevent-recurrent-urinary-tract-infections-in-uncircumcised-male-infants-a-pilot-study-100632010","NCT07508124","Topical Steroids to Prevent Recurrent Urinary Tract Infections in Uncircumcised Male Infants: a Pilot Study","Topical Steroids to Prevent Recurrent Urinary Tract Infections in Uncircumcised Male Infants With a First Febrile Urinary Tract Infection: a Multi-center Pilot Study","STRUMI-T","Inclusion Criteria:\n\n1. Uncircumcised male infants \\\u003C 6 months old\n2. Both physician and laboratory confirmed diagnosis of first UTI\n3. Fever (temperature ≥38.0 C) or hypothermia (temperature \\\u003C36.0 C) per ED\u002Fhospitalization or parental report\n\nExclusion Criteria:\n\n1. Legal guardian not available to provide informed consent\n2. Infant in Child Protective Services (CPS) custody\n3. Legal guardian would like Urology referral for circumcision\n4. Circumcision is medically indicated due to recurrent episodes of balanitis or ballooning of foreskin during urination\n5. Past diagnosis of penile abnormalities (diagnoses of epispadius, hypospadias or congenital penile curvature (chordee))\n6. Prior use of topical steroid therapy for phimosis\n7. History of hypersensitivity to topical steroids\n8. Legal guardian is not fluent in English OR Spanish\n9. Foreskin assessed to be fully retractable\n10. Open wounds present on penis or in groin region","0 Months","5 Months",{"count":92,"type":21},40,[61],"The goal of this smaller clinical trial is to evaluate the study design of this research to help prepare for a larger research study in the future. The future larger study would focus on whether steroid cream can reduce recurrent urinary tract infections in male infants, who are not circumcised.\n\nMale infants, who are enrolled in this study, would receive either the steroid cream or a placebo cream (a look alike cream without steroids). The cream would be applied twice a week for four weeks. Then there would be two follow up visits with the research team to measure whether the infant experienced any urinary tract infections and to measure parent perceptions of their experience participating in the study.",[27],[97,98,99,100],"urinary tract infection","uncircumcised male infants","betamethasone cream","steroid cream","RECRUITING","2026-03-27",{"date":104,"type":38},"2026-04-02",{"date":106,"type":21},"2026-04",{"date":108,"type":21},"2027-12",{"name":110,"class":45},"Baylor College of Medicine",3,{"id":113,"slug":114,"hasResults":11,"nctId":115,"briefTitle":116,"officialTitle":117,"acronym":4,"eligibilityCriteria":118,"healthyVolunteers":11,"sex":55,"minAge":18,"maxAge":4,"enrollmentInfo":119,"targetDuration":4,"studyType":22,"phases":121,"briefSummary":123,"conditions":124,"keywords":126,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":129,"lastUpdatePostDateStruct":130,"startDateStruct":132,"completionDateStruct":134,"leadSponsor":136,"locationsCount":46},"100624559","de-implementing-preop-urine-testing-100624559","NCT07411209","De-implementing PreOp Urine Testing","De-implementation of Unnecessary Pre-Operative Urine Testing","Inclusion Criteria:\n\n* Medical Centers part of the Veterans Affairs Health Administration (VAMCs)\n* VAMCs that perform standard, intermediate, or advanced surgical procedures\n* VAMCs in which perioperative urine testing is performed among greater than 10% of their non-urologic, non-transplant surgery procedures\n\nExclusion Criteria:\n\n* VAMCs that only perform ambulatory surgery (outpatient\u002Fday surgery only)\n* VAMCs that do not perform urine testing among at least 10% of their non-urologic, non-transplant surgery procedures\n* VAMCs that already have implemented interventions to reduce perioperative urine testing\n* VAMCs' units performing genitourinary or transplant surgeries\n* Database of patients with a diagnosis of urinary tract infection within 30 days before surgery",{"count":120,"type":21},6,[122],"NA","This is a randomized study to evaluate the effectiveness and implementation of an intervention to decrease unnecessary urine testing for surgical patients (Less is More for Surgical Urine Testing) across six geographically diverse Veterans Affairs Medical Centers. The intervention will unfold over two years, in three phases: control, intervention, and sustainability.",[27,125],"Asymptomatic Bacteriuria",[127,128],"antibiotic stewardship","kicking cauti","2026-02-10",{"date":131,"type":38},"2026-02-13",{"date":133,"type":21},"2026-12-31",{"date":135,"type":21},"2030-12-31",{"name":137,"class":138},"VA Office of Research and Development","FED",{"id":140,"slug":141,"hasResults":11,"nctId":142,"briefTitle":143,"officialTitle":144,"acronym":4,"eligibilityCriteria":145,"healthyVolunteers":11,"sex":55,"minAge":18,"maxAge":4,"enrollmentInfo":146,"targetDuration":4,"studyType":22,"phases":148,"briefSummary":149,"conditions":150,"keywords":152,"overallStatus":101,"whyStopped":4,"lastUpdateSubmitDate":158,"lastUpdatePostDateStruct":159,"startDateStruct":161,"completionDateStruct":163,"leadSponsor":165,"locationsCount":46},"100569048","chlorhexidine-antiseptic-irrigation-of-the-bowel-segment-during-radical-cystectomy-and-urinary-diversion-100569048","NCT06689176","Chlorhexidine Antiseptic Irrigation of the Bowel Segment During Radical Cystectomy and Urinary Diversion","Chlorhexidine Antiseptic Irrigation of the Bowel Segment During Radical Cystectomy and Urinary Diversion After Chlorhexidine Irrigation in Patients Undergoing Radical Cystectomy","Inclusion Criteria:\n\n* Provision of signed and dated informed consent form.\n* Stated availability for the duration of the study, and willingness to comply with all study procedures, including willingness to adhere to twice daily irrigation of neobladder or ileal conduit.\n* Male or female, ≥ 18 years of age\n* Confirmed diagnosis of bladder cancer\n* Candidate for radical cystectomy with urinary diversion\n* ECOG performance status of 0-2\n* Serum creatinine ≤ 1.5 mg\u002FdL\n\nExclusion Criteria:\n\n* Has undergone or planned to undergo urinary diversion other than ileal conduit or neobladder.\n* Pregnancy or lactation.\n* Known allergic reactions to components of the Irrisept irrigating system, chlorhexidine.\n* Patient must not have any uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness\u002Fsocial situations that, in the opinion of the investigator, would limit compliance with study requirements.",{"count":147,"type":21},23,[122],"This is a single arm, interventional pilot study of using chlorhexidine irrigation intra-operatively and post-operatively among patients undergoing radical cystectomy with urinary diversion. The intervention comprises of using irrigation of ileal conduit or ileal neobladder intra-operatively and then for irrigation of either post-surgery with Irrisept ®. The sterilization of urine will be assessed at 10 days after cystectomy. Incidence of symptomatic urinary tract infections within the 30-day post-operative period will be estimated.",[151,27],"Bladder Cancer",[151,153,154,155,156,157],"Radical Cystectomy","Ileal Conduit","Neobladder","Chlorhexidine Gluconate","Irrisept","2025-12-08",{"date":160,"type":38},"2025-12-15",{"date":162,"type":38},"2024-08-01",{"date":164,"type":21},"2026-07-01",{"name":166,"class":45},"Icahn School of Medicine at Mount Sinai",{"id":168,"slug":169,"hasResults":11,"nctId":170,"briefTitle":171,"officialTitle":172,"acronym":4,"eligibilityCriteria":173,"healthyVolunteers":174,"sex":55,"minAge":18,"maxAge":4,"enrollmentInfo":175,"targetDuration":4,"studyType":22,"phases":177,"briefSummary":178,"conditions":179,"keywords":182,"overallStatus":101,"whyStopped":4,"lastUpdateSubmitDate":187,"lastUpdatePostDateStruct":188,"startDateStruct":190,"completionDateStruct":192,"leadSponsor":194,"locationsCount":46},"100611333","the-impact-of-irrisept-in-reducing-urinary-tract-infection-during-urethral-catheter-removal-100611333","NCT07239219","The Impact of Irrisept in Reducing Urinary Tract Infection During Urethral Catheter Removal.","To Determine the Efficacy of Irrisept in Reducing Urinary Tract Infection During Urethral Catheter Removal.","Inclusion Criteria:\n\n1. Presenting to the urology clinic for catheter removal\n2. Must be 18 years or older.\n3. The patient must be able to understand and willing to provide informed consent as described in this study protocol.\n4. Must be willing to complete a post-catheter removal survey\n\nExclusion Criteria:\n\n1. Allergy or adverse reaction to chlorohexidine gluconate\n2. Under the age of 18\n3. Refuse to provide informed consent\n4. On antibiotic therapy for any indication.\n5. Women who are pregnant or breastfeeding\n6. Signs of skin or systemic infection\n7. Patients undergoing catheter exchange",true,{"count":176,"type":21},300,[122],"Given the high burden of post-catheter removal UTIs, this study aims to evaluate Irrisept instillation as a non-antibiotic intervention to reduce infection rates. By comparing Irrisept to saline irrigation, the study will provide critical insights into the efficacy of antiseptic bladder irrigation in preventing UTIs while minimizing antibiotic use. If successful, this approach could lead to new clinical guidelines for catheter removal protocols, improving patient outcomes and reducing healthcare costs.",[27,180,181],"Antibiotic","Catheter Infection",[183,184,185,186],"UTI","antibiotic","Catheter infection","CAUTI","2025-11-16",{"date":189,"type":38},"2025-11-20",{"date":191,"type":21},"2025-12-31",{"date":193,"type":21},"2028-01-01",{"name":195,"class":45},"Ohio State University",{"id":197,"slug":198,"hasResults":11,"nctId":199,"briefTitle":200,"officialTitle":201,"acronym":4,"eligibilityCriteria":202,"healthyVolunteers":11,"sex":55,"minAge":4,"maxAge":4,"enrollmentInfo":203,"targetDuration":4,"studyType":205,"phases":4,"briefSummary":206,"conditions":207,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":208,"lastUpdatePostDateStruct":209,"startDateStruct":211,"completionDateStruct":213,"leadSponsor":215,"locationsCount":46},"100608685","microbiological-characterization-and-antibiotic-resistance-profiling-of-providencia-spp-an-emerging-pathogen-isolated-from-urinary-tract-infections-100608685","NCT07204769","Microbiological Characterization and Antibiotic Resistance Profiling of Providencia Spp,: An Emerging Pathogen Isolated From Urinary Tract Infections","Microbiological Characterization and Antibiotic Resistance Profiling of Providencia Spp,: An Emerging Pathogen Isolated From Urinary Tract Infections.","Inclusion Criteria:\n\nPatients with UTI diagnosed through clinical examination and urine analysis. Informed consent will be obtained from each patient before Participation in the study.\n\nExclusion Criteria:\n\n1. Patients currently on antibiotics.\n2. Patients with any anatomical abnormalities in the urinary tract C) Patients having UTI by gram +ve organisms.",{"count":204,"type":21},241,"OBSERVATIONAL","Aims of the Research:\n\n1. Isolation and identification of Providencia spp. from UTIs.\n2. Genotypic confirmation of Providencia isolates.\n3. Determination of antimicrobial sensitivity patterns of isolated Providencia spp.\n4. Characterization of some virulence factors of Providencia spp.\n5. Molecular characterization of multidrug-resistance gene antibiotics.\n6. Determination of risk factors for Providencia UTIs.",[27],"2025-09-30",{"date":210,"type":38},"2025-10-02",{"date":212,"type":21},"2026-05-01",{"date":214,"type":21},"2027-09",{"name":216,"class":45},"Assiut University",{"id":218,"slug":219,"hasResults":11,"nctId":220,"briefTitle":221,"officialTitle":222,"acronym":223,"eligibilityCriteria":224,"healthyVolunteers":11,"sex":55,"minAge":225,"maxAge":57,"enrollmentInfo":226,"targetDuration":4,"studyType":22,"phases":227,"briefSummary":228,"conditions":229,"keywords":234,"overallStatus":101,"whyStopped":4,"lastUpdateSubmitDate":236,"lastUpdatePostDateStruct":237,"startDateStruct":239,"completionDateStruct":241,"leadSponsor":243,"locationsCount":46},"100600150","perspectives-on-antibiotics-and-tracking-symptoms-in-children-100600150","NCT07093749","Perspectives on Antibiotics and Tracking Symptoms in Children","PATSy Perspectives on Antibiotics and Tracking Symptoms in Children - a Mixed Methods Feasibility Study","PATSy","Inclusion Criteria:\n\n* Between the ages of ≥ 4 years and ≤ 17 years at enrolment.\n* Diagnosed with any of the following at RCH ED: urinary tract infection (UTI), cellulitis, impetigo, pharyngitis, tonsillitis, respiratory tract infections, otitis media.\n* Prescribed oral antibiotics (either immediately or as switch from IV antibiotics after transfer to HITH) as standard of care due to having uncomplicated infection as deemed by their treating doctor.\n* Parent\u002Fguardian provides a signed and dated informed consent form.\n\nExclusion Criteria:\n\n\\- Parent\u002Fguardian does not speak English","4 Years",{"count":176,"type":21},[122],"The study will assess families' perspectives and decision-making regarding the duration of oral antibiotic courses prescribed to children (4-17 years) who present with uncomplicated bacterial infections at the Royal Children's Hospital (RCH) Emergency Department (ED). The study will involve (i) children discharged from ED on oral antibiotics and (ii) children transferred to Hospital-in-the-Home (HITH) on IV antibiotics who then switch to oral antibiotics. In addition, the study will assess how feasible and acceptable it is to track children's symptoms via the Garmin Smartwatch and the WeGuide platform (WeGuide is a patient engagement software platform that allows for enrolment, consent, and data collection \\[via questionnaires\u002Fsurveys and from the Garmin Smartwatches\\] through a singular platform).",[27,64,230,231,232,65,233],"Impetigo","Pharyngitis","Tonsillitis","Otitis Media",[70,69,235,68],"Digital Health","2025-09-17",{"date":238,"type":38},"2025-09-22",{"date":240,"type":38},"2025-09-16",{"date":242,"type":21},"2026-08",{"name":80,"class":45},{"id":245,"slug":246,"hasResults":11,"nctId":247,"briefTitle":248,"officialTitle":248,"acronym":4,"eligibilityCriteria":249,"healthyVolunteers":11,"sex":55,"minAge":250,"maxAge":4,"enrollmentInfo":251,"targetDuration":4,"studyType":205,"phases":4,"briefSummary":253,"conditions":254,"keywords":258,"overallStatus":101,"whyStopped":4,"lastUpdateSubmitDate":264,"lastUpdatePostDateStruct":265,"startDateStruct":267,"completionDateStruct":269,"leadSponsor":271,"locationsCount":46},"100584998","urinary-infection-and-colonization-in-bone-procedures-100584998","NCT06896643","Urinary Infection and Colonization in Bone Procedures","Inclusion Criteria:\n\n* Age over 65 years, including\n* Elective or acute trauma\u002Forthopedic bone surgery\n* Urine examination as part of pre-anesthetic examination, urine + sediment, in case of suspicion - bacteriological examination\n* Signed informed consent for research as part of pre-anesthetic examination (I or II), respecting informed consent as an expression of the patient's \"free will\"\n\nExclusion Criteria:\n\n* Negative finding in urine: chemical examination + sediment preoperatively\n* Respondent under the influence of premedication, alcohol, or drugs\n* Sensory impairment (blindness)\n* Delirious preoperative state\n* Severe mental disorder\n* Sopor\n* coma\n* Septic state\n* Acute respiratory failure\n* Disagreement with participation in the study","65 Years",{"count":252,"type":21},80,"For seniors aged 65 and over (inclusive) undergoing surgical procedures (bone surgery, traumatology, orthopedics) in an acute or elective setting, the relationship between preoperative urinary tract infection\u002Fcolonization (within 30 days before the procedure) and the occurrence of predefined postoperative complications (monitoring during the patients' hospitalization) will be observed",[27,255,256,257],"Complications","Urinary Tract Infection (Diagnosis)","Frailty",[259,260,261,262,263],"urinary","tract","infection","colonization","postoperative complications","2025-07-06",{"date":266,"type":38},"2025-07-08",{"date":268,"type":38},"2025-06-01",{"date":270,"type":21},"2026-06-01",{"name":272,"class":45},"Tomas Bata Hospital, Czech Republic",{"id":274,"slug":275,"hasResults":11,"nctId":276,"briefTitle":277,"officialTitle":278,"acronym":4,"eligibilityCriteria":279,"healthyVolunteers":11,"sex":280,"minAge":281,"maxAge":4,"enrollmentInfo":282,"targetDuration":4,"studyType":22,"phases":284,"briefSummary":285,"conditions":286,"keywords":4,"overallStatus":101,"whyStopped":4,"lastUpdateSubmitDate":290,"lastUpdatePostDateStruct":291,"startDateStruct":293,"completionDateStruct":295,"leadSponsor":297,"locationsCount":46},"100563233","effectiveness-of-the-ai-supporter-in-reducing-urinary-tract-infections-100563233","NCT06613503","Effectiveness of the AI-Supporter in Reducing Urinary Tract Infections","Testing the Effectiveness of the AI-Supporter in Reducing Urinary Tract Infections, Incontinence-associated Dermatitis and Caregiving Costs for Incontinence Patients","Inclusion Criteria:\n\n* Participants must have been bedridden for at least 3 months and have urinary and\u002For fecal incontinence.\n* Female participants aged over 20 years old.\n* Participants must be capable of wearing the AI-supporter device during the study period.\n\nExclusion Criteria:\n\n* Participants with severe skin conditions unrelated to incontinence.\n* Participants with current urinary tract infections or incontinence-associated dermatitis at the time of enrollment.\n* Participants who are unable to provide informed consent or have a legal representative to do so.","FEMALE","20 Years",{"count":283,"type":21},60,[122],"The \"AI Supporter,\" an intelligent excretion management robot, leverages artificial intelligence-based vision recognition to autonomously detect and cleanse affected areas, followed by drying and changing the diaper, thereby reducing caregiver strain and enhancing care quality. This study aims to assess the efficacy of the \"AI Supporter\" in decreasing the incidence of urinary tract infections and incontinence-associated dermatitis among incontinent patients, in addition to exploring its cost-effectiveness.\n\nAdopting an experimental (two groups) and longitudinal design, this research utilizes both convenience and random sampling strategies. The study anticipates recruiting 60 female subjects who have been confined to bed for more than three months with urinary and\u002For fecal incontinence. Participants will intermittently use the AI Supporter over a 14-day period. Measurement tools include routine urine analysis.",[287,27,288,289],"Incontinence","Incontinence-associated Dermatitis","Cost-effectiveness","2024-09-23",{"date":292,"type":38},"2024-09-26",{"date":294,"type":38},"2024-07-22",{"date":296,"type":21},"2025-10-31",{"name":298,"class":45},"China Medical University Hospital"]